Thromboembolic myocardial infarction after transcatheter aortic valve implantation: a spotlight on antithrombotic treatment post-TAVI
Vasileios Kamperidis
Anastasios Karlas
Georgios Sianos
Antonios Ziakas
Haralambos Karvounis
Stavros Hadjimiltiades
First Cardiology Department, AHEPA University Hospital, Aristotle University of Thessaloniki, Thessaloniki, Greece
摘要：The use of dual antiplatelet therapy for the first three-six months after transcatheter aortic valve implantation (TAVI) has beensuggested.[1,2] However, the additional benefit of anticoagulant therapy during the same period has conflicting data and even the guidelines from different cardiology societies are not in line;the American College of Cardiology/American Heart Association Guidelines recommend with an indication class Ⅱb the use of vitamin K anticoagulants with an international normalized ratio (INR) of 2.5 for the first three-months post-TAVI alongside with aspirin to avoid thromboembolic events, while the European Association of Cardiology Guidelines do not[1,2] This case report presents a thromboembolic event in the coronary arteries leading to myocardial infarction and death post-TAVI, diagnosed on autopsy by identifying the thrombi on the CoreValve stent.
机标关键词：
论文发表日期：2021-04-28
在线出版日期：2025-08-15（本平台首次上网日期，不代表文献的发表时间）
页数：3( 316-318 )